Aminoglycosides are a therapeutically important class of antibiotics that inhibit bacterial protein synthesis and a number of viral and eukaryotic functions by blocking RNA-protein interactions. Vanadate-resistant Saccharomyces cerevisiae mutants with defects in Golgi-specific glycosylation processes exhibit growth sensitivity to hygromycin B, an aminoglycoside [Ballou, L., Hitzeman, R. A., Lewis, M. S. & Ballou, C. E. (1991) Proc. Nall. Acad. Sci. USA 88,[3209][3210][3211][3212]. Here, evidence is presented that glycosylation is, in and of itself, a key factor mediating aminoglycoside sensitivity in yeast. Examination of mutants with a wide range of glycosylation abnormalities reveals that all are sensitive to aminoglycosides. This effect is specific to aminoglycosides and not merely a consequence of increased permeability of the yeast mutants to drugs. Furthermore, inhibition of glycosylation in wild-type cells leads to a marked increase in their sensitivity to aminoglycosides. These results establish that a defect in glycosylation is sufficient to render yeast cells susceptible to these clinically important drugs. Further, they suggest that a molecule which prevents the uptake or mediates removal of aminoglycosides requires glycosylation for its activity. Perhaps more importantly, this finding on drug sensitivity provides the most powerful screen to date to identify mutants and thereby to isolate genes involved in all aspects of N-linked glycosylation.
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Aminoglycosides are known to interfere with RNA-protein interactions. These antibiotics inhibit bacterial translation by interacting with the 16S ribosomal RNA (1) (2) (3) . In eukaryotes, aminoglycosides block splicing of group I introns by binding to a specific RNA motif (4, 5) . Certain members of the aminoglycoside family selectively block the binding of the human immunodeficiency virus (HIV) Rev protein to its cognate RNA recognition element (6) . Inhibition of HIV replication by members of this family has been demonstrated (6) , qualifying aminoglycosides as important antiviral agents that likely mediate their effect through sequence-specific RNA interactions. However, the efficacy of these drugs as therapeutic agents is limited because of poor intracellular uptake in eukaryotic cells.
Yeast mutants that have defects in Golgi-specific glycoprotein processing are selectively enriched by growth resistance to sodium vanadate and sensitivity to the aminoglycoside hygromycin B (7) . Five hygromycin-sensitive complementation groups that have Golgi-specific glycosylation defects have been identified previously. Three of these are allelic to the well-characterized mnn8, mnn9, and mnnlO mutations, and the remaining two are allelic to the previously unidentified mutations vrgl and vrg4 (7) . All of these mutants are defective in glycoprotein modifications that affect the elongation of outerchain carbohydrates in the Golgi complex (8) . It tants and their genetic analyses will be described elsewhere.) Surprisingly, two mutants were isolated that are defective in very early steps of glycosylation that take place in or before the endoplasmic reticulum (ER). The isolation of mutants with defects in early steps in the glycosylation pathway suggested that hygromycin B sensitivity is not due to defects in Golgi-specific functions. To understand how a molecule that binds to RNA impinges upon glycosylation within the secretory pathway, I examined the effect of aminoglycosides on the growth characteristics of yeast glycosylation mutants. In the present work, I report the results of experiments that demonstrate that aminoglycoside hypersensitivity is due, at least in part, to defects in glycosylation. These experiments demonstrate that hygromycin B sensitivity is a phenotype that is not restricted to mutants with Golgi-specific glycosylation defects, but rather is common to a large number of yeast mutants with defects in all aspects of glycosylation. Drug sensitivity, therefore, provides a powerful selection technique that can be used for the cloning of the wild-type genes defined by these mutations.
MATERIALS AND METHODS
Strains, Plasmids, and Media. The following Saccharomyces cerevisiae strains were used in this study: DBY747-3D2 (MA Ta rad52-8::TRPl trpl-289 leu2-3,112 his3-AJ ura3-52) (R. Rothstein, Columbia University, New York); PRY55 (MATa algl-l ura3-52) (9); PRY212 (MATa alg2-1 ura3-52) (10); PRY90 (MATa alg3-1 ade2-101 ura3-52) (10); PRY95 (MA Ta alg4-4 ura3-52), PRY98 (MATa alg5-1 ade2-101 ura3-52) (10) (P. Robbins, Massachusetts Institute of Technology, Cambridge); RSY4 (MATa secl8-1 glsl-l) (11) , LB1OB (MA Ta mnnl), LB116A (MATa mnn2), and TH210D (MAT a mnnl mnn2 ura3-52) (Berkeley Genetics Stock Center); mnn8 (MATa mnn8gall CUPJ), mnn9 (MATa mnn9gall CUP1), and mnnlO (MATa mnnlO gall CUP1) (C. Ballou, University of California, Berkeley); MA9-D (MATa wbpl-l ade2-101 his3-A200 ura3-52 lys2-801) (12) These yeast mutants failed to grow on YPAD plates supplemented with 50 ,g of hygromycin B per ml, a concentration that did not inhibit the growth of the parental, wild-type strains. Dol, dolichyl.
*These mutants will be 'described in detail elsewhere. ndyl.4 and -17.4 are allelic to the oligosaccharyltransferase mutant, m163 (13 (7) .
With the exception of camptothecin (see below), all drugs were resuspended in water or 50% ethanol to prepare concentrated stock solutions. Hygromycin B (Sigma) was purchased as an aqueous solution supplied at 460,000 units/ml. According to the manufacturer, this represents a concentration of 460 mg/ml, and the stock was diluted as required by using this number as a conversion factor. All drugs were appropriately diluted into cooled, autoclaved medium just before pouring the agar plates.
Assay of Camptothecin and Cycloheximide Sensitivity. To measure drug sensitivity to camptothecin and cycloheximide, approximately 107 yeast cells were spread as a lawn on YPAD agar plates. A 5-mm diameter plug of agar from the center of the plate was removed to create a well. To measure camptothecin sensitivity, 100 ,ul of 20 mM camptothecin (kindly provided by Rolf Sternglanz, State University of New York) dissolved in dimethyl sulfoxide/methanol (1:1) was placed in the well and plates were incubated at 30°C for 2 days, as described (14) . To measure cycloheximide sensitivity, 10 ,ul of a 10 mg/ml solution of cycloheximide dissolved in ethanol was placed in the well, and plates were incubated as described above. In both cases, the zone of inhibition produced around the well is a measure of the degree of cell sensitivity toward the drug.
Inhibition 
RESULTS AND DISCUSSION
A number of glycosylation mutants have been isolated which are reported to be hygromycin sensitive (7) . All of these mutants are defective in processes that affect glycosylation reactions that occur in the Golgi complex. This suggested a relationship between abnormal glycosylation and hygromycin B sensitivity. To examine this further, other well-characterized glycosylation mutants were tested for drug sensitivity. The mutants examined are defective in glycosylation steps that range from those catalyzed in or before the ER, to those catalyzed in the Golgi complex (15, 16) . With two exceptions, described below, every glycosylation mutant that was tested exhibited hygromycin B sensitivity. Table 1 is a list of glycosylation mutants that are sensitive to hygromycin B, including those five that were previously described (7) . Of the individual glycosylation mutants that were tested, only two failed to display sensitivity: mnnl and mnn2. These mutants are defective in the addition of a-1,3-linked (mnnl) (22) Fig. 1A . All of the wild-type parental yeast strains grow on medium supplemented with 50 ,ug of hygromycin B per ml (Fig. 1A) and become growth inhibited only at concentrations above 100 ,ug/ml (data not shown). In contrast, all of the glycosylation mutants tested were completely inhibited on plates containing 50 ,ug of hygromycin B per ml, demonstrating that hygromycin B sensitivity is a mutant phenotype and is not due to strain variation. The degree of sensitivity at other concentrations varied among the different mutants. Those mutants affected at the earliest steps of glycoprotein modifications, such as the alg mutants and the oligosaccharyltransferase mutants, were inhibited by less than 10 ,ug of hygromycin B per ml. mnn mutations, which affect later steps of the glycosylation pathway, required 30-50 jig of hygromycin B per ml for growth inhibition (data not shown). The results of this experiment indicate that hygromycin B sensitivity is a previously unrecognized phenotype common to a wide range of mutants that have different degrees of glycosylation abnormalities.
Why should defective glycosylation lead to drug sensitivity? The yeast cell wall is composed primarily of glucan, chitin, and mannoproteins (20) . Therefore, one possibility is that glycosylation mutants may be permeable to many drugs due to cell wall defects. To test this, the mutants defective at both early and late steps of glycosylation were grown on medium supplemented with a variety of drugs. Those examined included nonaminoglycoside antibiotics and other members of the aminoglycoside family. A summary of these data is shown in Table  2 . Several conclusions can be drawn from the results of this survey. None of the nonaminoglycosides tested had any differential effect upon the mutants. Nonaminoglycoside antibiotics that have related modes of action, such as inhibitors of protein synthesis (e.g., erythromycin and chloramphenicol), had no effect on either the wild type or mutants at any concentration used. As a test for hyperpermeability to nonaminoglycosides that are known to effect yeast, growth inhibition by camptothecin and cycloheximide was examined. Camptothecin is a cytotoxic alkaloid known to damage DNA in S. cerevisiae at moderate concentrations by acting through DNA topoisomerase I (14) . This drug was no more toxic to glycosylation mutants than wild-type cells at the concentration used, though it inhibited the growth of a known hypersensitive DNA repair mutant, radS2 (14) (Fig. 2A) . Similarly, cycloheximide, an inhibitor of protein synthesis, inhibited the growth of wildtype cells to the same degree as any of the glycosylation mutants tested (Fig. 2B) . These results suggested that these mutants are not hypersensitive to drugs in general.
Of the drugs tested, only the aminoglycosides specifically inhibit the growth of glycosylation mutants but not wild-type cells ( Table 2 ). The most potent aminoglycoside inhibitors were hygromycin B and gentamicin (G418). Gentamicin blocked growth of early glycosylation mutants at concentrations below 10 ,ug/ml. Inhibition of wild-type cells requires 200 ,ug/ml to inhibit growth (Fig. 3) . Other aminoglycosides that were effective included neomycin and kanamycin, though these required higher concentrations to fully inhibit the growth of mutants defective at late stages of glycosylation. While the possibility cannot be ruled out that the effect of aminoglycosides may be due to a generalized change in the permeability properties of these cells, these results suggest that glycosylation mutants are specifically sensitive to aminoglycosides. All of the mutants have glycosylation defects. This does not, however, establish that drug sensitivity is a result of abnormal glycosylation. Whether or not abnormal glycosylation is sufficient to cause drug sensitivity was examined by testing the effect of glycosylation inhibition in wild-type cells. Wild-type cells were grown in suspension in the presence or absence of a sublethal concentration of tunicamycin (5 gg/ml), a specific inhibitor of N-linked glycosylation. Aliquots of the cell suspension were then plated on solid medium, with or without added hygromycin B. Cells that had been exposed to tunicamycin completely failed to grow on plates supplemented with hygromycin B. Tunicamycin, at the concentration used, did not lead to cell death, as these same tunicamycin-treated cells grew well on plates lacking hygromycin B (Fig. 4) . This result strikingly demonstrates that inhibition of glycosylation in wildtype cells results in drug sensitivity. Furthermore, it implies that in mutant cells, drug sensitivity is caused by abnormal glycosylation. Three important observations are described here. First, almost all glycosylation mutants tested, both early-stage and late-stage mutants, are sensitive to the aminoglycoside hygromycin B. The only exceptions, mnnl and mnn2, proved sensitive when the double mutant was tested. Among the different mutants, the increased sensitivity to this drug is substantial, varying from 4-to 20-fold relative to wild-type yeast. On the basis of these results, a strong prediction is that other yeast mutants with mutations that affect glycosylation will also be hygromycin B sensitive. Second, these same mutants are sensitive to other aminoglycosides but not to other drugs tested. Third, in wild-type cells, inhibition of glycosylation by tunicamycin results in sensitivity to hygromycin B. This last observation demonstrates that abnormal glycosylation, specifically glycosylation of an N-linked glycoprotein, is sufficient to render cells susceptible to the effects of aminoglycosides.
The conclusion from these data is that abnormal glycosylation results in an altered sensitivity or permeability to these clinically important drugs. This may be due to a defect in a cell wall or plasma membrane component(s) that either allows uptake or prevents export of aminoglycosides. Alternatively, an N-linked glycoprotein within the endomembrane system may be involved in the detoxification of aminoglycosides once they have entered the cell. If this were the case, the data presented here suggest that the functional activity or localization of this molecule is exquisitely sensitive to its glycosylation state. Accordingly, we are using aminoglycoside sensitivity as a powerful tool for the isolation of genes defined by novel and gentamicin 1 
